AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00411424
Drug: ASK8007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00411424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT01741922
Drug: Placebos morning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
Trial: NCT00286377
Drug: prosaptide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04364555
Drug: Placebo/Klobetasol APL oral gel 0.025%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/active
Trial: NCT04364555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/placebo
Trial: NCT00606489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00741169
Drug: TMC435350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg taken by mouth once daily for 7 days
Trial: NCT00994903
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg orally, given 3-7 days pre-op and continued till 14 days post-op
Trial: NCT00994903
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Inert calcium lactate) tablets 3-7 days pre-op to 14 days post-op (as per experimental arm)
Trial: NCT01741922
Drug: Placebo evening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening \& placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
Trial: NCT01465022
Drug: Combined estrogen-progestin pill
RxNorm normalized name: estrogens, conjugated (USP) Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo
Trial: NCT01465022
Drug: Progestin-only pill
RxNorm normalized name: Prostin E2 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: .35 mg norethindrone once a day orally
Trial: NCT02086864
Drug: lactose/sucrose granule (Individualized homeopathic medicine treatment)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The homeopathic remedy (study medication) for each patient will be chosen from among the homeopathic medicines manufactured by Boiron Canada and currently approved for sale in Canada by Health Canada. As per classical homeopathy practice, once the most appropriate homeopathic remedy has been chosen, it will be prescribed by the homeopath according to her/his clinical judgment (maximum on a daily basis, 3 times per day, minimum 1 dose (or zero doses on the second consult or later)) with administration instructions given to the parent and patient as appropriate. Water dosing, in which a lactose/sucrose granule remedy is dissolved in 250 ml of water will be used based on the homeopath's clinical judgment. Only one remedy will be administered at a time.
Trial: NCT02086864
Drug: Placebo lactose/sucrose pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02868424
Drug: fRPE cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fRPE cells transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure
Trial: NCT02026011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill, matched to the active study medication in capsule size and color
Trial: NCT03372161
Drug: SP-102
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection
Trial: NCT03372161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection
Trial: NCT06353477
Drug: EPs® 7630
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPs® 7630 is an extract from the roots of Pelargonium sidoides, drug-extract ratio 1 : 8-10, extraction solvent ethanol 11% (w/w). The patients were divided into two groups: (i) group 1 received herbal drug EPs® 7630 by oral route \[Umca® solution; (3x10 drops; between 1-5 years of age, 3x20 drops; 6-12 years of age, 3x30 drops for children \&gt;12 years of age)\] for 7 days and (ii) group 2 (control group) did not receive any herbal medication. The medication was administered orally, at least 30 minutes before or after meals. Patients in both groups were prescribed paracetamol (10 mg/kg/dose, 4 times a day, maximum 4,000 mg/day.) as an antipyretic agent. Temperature measurement was made at home and in the hospital via the axillary route.
Trial: NCT03395496
Drug: Biodentine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biodentine pulpotomy agent
Trial: NCT02495285
Drug: Gelofusine 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02495285
Drug: Gelaspan 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01732536
Drug: S8 Sinus Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
Trial: NCT01836289
Drug: High-dose Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00641693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00368056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT01332214
Drug: AZD2820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injection in abdomen or Thigh
Trial: NCT01332214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Injection in abdomen or Thigh
Trial: NCT03567889
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive adjuvant therapy at the investigator's discretion following the surgery.
Trial: NCT01281111
Drug: BG00012 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01281111
Drug: ASA matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05353686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the placebo arm will receive an oral tablet containing no active drug twice daily
Trial: NCT01781884
Drug: Gamma Aminobutyric Acid (GABA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two dosages will be used in this study. GABA: 50mg/kg/day and 100mg/kg/day
Trial: NCT01781884
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03323684
Drug: Ketorolac analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases and then every 8 hours.
Trial: NCT03323684
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, Fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes. Postoperatively, Fentanyl boluses (20 micrograms) will be given if VAS is more than 3 and it might be repeated after 30 minutes until VAS is ≤ 3.
Trial: NCT00180037
Drug: Coenzyme Q10 Nanodispersion (Nanoquinone)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00180037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02890277
Drug: Fu Tiankang disposable vaginal filling suppository, Albothyl (Policresulen Solution) , and the gynecologic medical antimicrobial dressing gel (chitosan gel).
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00661830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00790049
Drug: ARRY-371797, p38 inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose and multiple dose, escalating
Trial: NCT00790049
Drug: Placebo; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT00517699
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 8g/m2 iv
Trial: NCT04602143
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apply 12.5mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 4 or 6 weeks until next IVF treatment.
Trial: NCT03046446
Drug: FX006 32 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intra-articular injection
Trial: NCT02015403
Drug: Standard Care + NAC (N -ACETYLCYSTEINE)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02015403
Drug: Standard Care (in control arm)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03500211
Drug: Lidoderm 5 % Topical Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine patch after cesarean section delivery.
Trial: NCT01012284
Drug: TMC207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg (4 tablets of 100 mg) of TMC207 will be administered as a single dose on Day 1 of the treatment period to participants of both the Panels (Panel A and Panel B)
Trial: NCT02618434
Drug: SPN-810 (18 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were randomized to receive SPN-810 9 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
Trial: NCT02618434
Drug: SPN-810 (36 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were randomized to receive SPN-810 18 mg twice each day with food, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
Trial: NCT02618434
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were randomized to receive Placebo twice each day with food, in the morning and in the evening, in addition to the stable dose of the optimized ADHD medication determined from the lead-in period. If initiating treatment before noon, patients should start with the morning dose; if afternoon, the evening dose.
Trial: NCT00548834
Drug: CDP870
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02582827
Drug: ABI-011
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABI-011 is a novel, albumin-bound formulation of a potent thiocolchicine analog, IDN 5404, with a mean particle size of approximately 100 nm.
Trial: NCT00994864
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One cycle of standard FOLFOX pre-operatively followed by 11 cycles of standard adjuvant FOLFOX chemotherapy.
Trial: NCT01265017
Drug: Estradiol, medroxyprogesterone, hydrocortisone, GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Estradiol 1mg every 8 hours administered orally~* Medroxyprogesterone 2.5 mg every 24 hours administered orally~* Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally~* Growth hormone 2 mg once a day administered by subcutaneous injection,
Trial: NCT01265017
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT03679949
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone
Trial: NCT01293812
Drug: placebo po
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a solution or a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated).
Trial: NCT02701205
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two vials of placebo twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
Trial: NCT01646814
Drug: PL2200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PL2200, containing 325 mg aspirin active ingredient
Trial: NCT00326443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffer placebo administered on Day 0.
Trial: NCT04335071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo-controlled intervention is one dose (100 mL) NaCl 0.9% intravenously administered after confirmation of progressive dyspnoea. Infusion time: 60 min. The procedure is repeated once if no clinical improvement in the 8-point WHO scale is observed.
Trial: NCT03666988
Drug: GSK3368715
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3368715 will be available with dosing strengths of 25 mg, 100 mg and 250 mg to be administered once daily as an oral capsule.
Trial: NCT03666988
Drug: GSK3368715
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3368715 will be available in Immediate release (IR) white film coated tablet with dosing strengths of 50 mg, 100 mg and 250 mg to be administered orally once daily .
Trial: NCT02708680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A pill containing no active drug ingredient
Trial: NCT01384851
Drug: Refresh Dry Eye Therapy
RxNorm normalized name: Refresh Dry Eye Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop both eyes four times daily for two weeks
Trial: NCT04390399
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Trial: NCT04390399
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
Trial: NCT02294032
Drug: Immunosuppressive Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care for patients post-transplant
Trial: NCT04326790
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment
Trial: NCT00659841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03532022
Drug: Chronocort®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone modified release capsules - 5mg, 10mg and 20mg.
Trial: NCT03532022
Drug: Standard Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject's standard care regimen upon entering the study; this could consist of hydrocortisone, dexamethasone, prednisone or prednisolone.
Trial: NCT01478022
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 200 mg daily, capsules
Trial: NCT00806260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 4 weeks
Trial: NCT02171689
Drug: [14C]- BIBW 2992 MA2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02712996
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule, 20-70 mg, each morning for 6 weeks.
Trial: NCT03111316
Drug: Cervidil 10 MG Vaginal Insert
RxNorm normalized name: Cervidil 10 MG Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone vaginal insert is a thin, flat, polymeric slab which is rectangular in shape with rounded corners contained within the pouch of an off-white knitted polyester retrieval system, an integral part of which is a long tape. Each slab is buff colored, semitransparent and contains 10 mg of dinoprostone in a hydrogel insert. An integral part of the knitted polyester retrieval system is a long tape designed to aid retrieval at the end of the dosing interval or earlier if clinically indicated. The finished product is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
Trial: NCT01677871
Drug: 2HRZE/4HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months
Trial: NCT01677871
Drug: 2HRLE/4HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months
Trial: NCT02057926
Drug: The effect of tetracycline in degradation and permeability of collagen membranes.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03333694
Drug: Cutaneous Cream application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cutaneous Cream application twice daily with experimental (CLL442)
Trial: NCT03333694
Drug: Placebo Cutaneous Cream application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cutaneous Cream application twice daily with placebo
Trial: NCT03654274
Drug: Estradiol/norethindrone acetate
RxNorm normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing co-formulated tablet of E2 (1.0 mg) and NETA (0.5 mg) administered orally once daily
Trial: NCT02701764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01938261
Drug: 0.45 % saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03761056
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered according to package insert
Trial: NCT01679483
Drug: FloSeal application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
Trial: NCT04459416
Drug: opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All study patients will receive the usual HSCT care and pain management regimens (usually opioids) as per standard practice at the study institution.
Trial: NCT03521700
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For patients who were assigned to receive intensive lipid lowering, 10 mg/d rosuvastatin was initially prescribed and target LDL-C was \< 1.8mmol/L. For patients who were assigned to receive conventional lipid lowering, 5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, \<3.3mmol/L.
Trial: NCT01576783
Drug: Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg DHA+ 200 mg AA per day for 6 months
Trial: NCT01082848
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD during 26 weeks
Trial: NCT01819272
Drug: Met DR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin delayed-release tablets
Trial: NCT01819272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo delayed-release tablets
Trial: NCT01887405
Drug: Adrenaline auto-injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be randomly assigned to use either the Jext or EpiPen first. The alternative auto-injector will then be used by the same subject in the second study session.~Valid for both Jext and Epipen:~Active ingredients: Adrenaline tartrate Dosage form: Prefilled auto-injector for single use, delivering one intramuscular injection Dose/strength: 150 μg Excipients: Sodium chloride, sodium metabisulphite (E223), hydrochloric acid (for pH adjustment), water
Trial: NCT02022709
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
Trial: NCT01856322
Drug: Sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one tablet 150mg twice daily
Trial: NCT01856322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet twice daily
Trial: NCT02359006
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline will be compared with placebo
Trial: NCT02359006
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be compared with minocycline
Trial: NCT00002493
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00830050
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg BID 7 days
Trial: NCT00830050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID 7 days